3O0E
| Crystal structure of OmpF in complex with colicin peptide OBS1 | Descriptor: | Colicin-E9, Porin OmpF, octyl beta-D-glucopyranoside | Authors: | Wojdyla, J.A, Housden, N.G, Korczynska, J, Grishkovskaya, I, Kirkpatrick, N, Brzozowski, A.M, Kleanthous, C. | Deposit date: | 2010-07-19 | Release date: | 2010-12-08 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (3.01 Å) | Cite: | Directed epitope delivery across the Escherichia coli outer membrane through the porin OmpF. Proc.Natl.Acad.Sci.USA, 107, 2010
|
|
1XCG
| Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF | Descriptor: | Rho guanine nucleotide exchange factor 11, Transforming protein RhoA | Authors: | Derewenda, U, Oleksy, A, Stevenson, A.S, Korczynska, J, Dauter, Z, Somlyo, A.P, Otlewski, J, Somlyo, A.V, Derewenda, Z.S. | Deposit date: | 2004-09-01 | Release date: | 2004-12-14 | Last modified: | 2024-02-14 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | The crystal structure of RhoA in complex with the DH/PH fragment of PDZRhoGEF, an activator of the Ca(2+) sensitization pathway in smooth muscle Structure, 12, 2004
|
|
6QM8
| Leishmania tarentolae proteasome 20S subunit apo structure | Descriptor: | Proteasome alpha1 chain, Proteasome alpha2 chain, Proteasome alpha3 chain, ... | Authors: | Rowland, P, Goswami, P. | Deposit date: | 2019-02-01 | Release date: | 2019-04-17 | Last modified: | 2019-12-18 | Method: | ELECTRON MICROSCOPY (3.3 Å) | Cite: | Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6QM7
| |
8OLU
| |
6T6R
| Human endoplasmic reticulum aminopeptidase 1 (ERAP1) in complex with (4aR,5S,6R,8S,8aR)-5-(2-(Furan-3-yl)ethyl)-8-hydroxy-5,6,8a-trimethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid | Descriptor: | (4~{a}~{R},5~{S},6~{R},8~{S},8~{a}~{R})-5-[2-(furan-3-yl)ethyl]-5,6,8~{a}-trimethyl-8-oxidanyl-3,4,4~{a},6,7,8-hexahydronaphthalene-1-carboxylic acid, 1,2-ETHANEDIOL, D-MALATE, ... | Authors: | Rowland, P. | Deposit date: | 2019-10-18 | Release date: | 2020-03-18 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.67 Å) | Cite: | Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen Presentation. J.Med.Chem., 63, 2020
|
|
5FV2
| Crystal structure of hVEGF in complex with VH domain antibody | Descriptor: | VASCULAR ENDOTHELIAL GROWTH FACTOR, VH DOMAIN ANTIBODY | Authors: | Chung, C, Batuwangala, T. | Deposit date: | 2016-02-02 | Release date: | 2016-02-17 | Last modified: | 2019-05-15 | Method: | X-RAY DIFFRACTION (3.45 Å) | Cite: | Novel Interaction Mechanism of a Domain Antibody Based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency Than Ranibizumab and Bevacizumab and Improved Capacity Over Aflibercept. J.Biol.Chem., 291, 2016
|
|
5FV1
| Crystal structure of hVEGF in complex with VK domain antibody | Descriptor: | VASCULAR ENDOTHELIAL GROWTH FACTOR A, VK DOMAIN ANTIBODY | Authors: | Chung, C, Walker, A. | Deposit date: | 2016-02-02 | Release date: | 2016-02-17 | Last modified: | 2019-05-15 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Novel Interaction Mechanism of a Domain Antibody Based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency Than Ranibizumab and Bevacizumab and Improved Capacity Over Aflibercept. J.Biol.Chem., 291, 2016
|
|